Not a traditional drug phase: testing Epinephrine 1:100,000 for Gastric Neoplasms
This prospective, randomly assigned, single-center trial compares two epinephrine concentrations (1:100,000 and 1:500,000) in the submucosal injection solution used during gastric endoscopic submucosal dissection. The study evaluates whether the lower epinephrine concentration can maintain procedural efficiency while reducing epinephrine dose, without compromising hemostatic how well it works or safety.
Official registry: https://clinicaltrials.gov/study/NCT07920068 · Unidade Local de Saúde do Alto Ave, EPE · enrollment listed as 100
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Epinephrine 1:100,000, or Epinephrine 1:500,000. The registry lists allocation as randomized. This prospective, randomly assigned, single-center trial compares two epinephrine concentrations (1:100,000 and 1:500,000) in the submucosal injection solution used during gastric endoscopic submucosal dissection.
They plan to enroll about 100 people at Guimarães. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Optimal Epinephrine Concentration in Gastric Endoscopic Submucosal Dissection: A Prospective Randomized Trial
Interventions: Epinephrine 1:100,000, Epinephrine 1:500,000
Primary outcome (registry wording): Gastric ESD procedure time
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Age 18 years or older
- Patients scheduled to undergo gastric endoscopic submucosal dissection (ESD) for a dysplastic or neoplastic gastric lesion
Who the registry excludes
- Contraindication to any component of the submucosal injection solution used in the study
- Any clinical condition considered by the investigator to preclude safe participation in the study
Public study contact (from the registry)
Mariana Souto, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Unidade Local de Saúde do Alto Ave — Guimarães, Braga District, Portugal (recruiting)
FAQ about this NCT record
Is NCT07920068 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07920068?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07920068?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary